Metrics as of 10/13/2026, 06:34 PM (Berlin time), refresh in progress.
GH Research Stock
GH Research PLC
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- CEO
- Velichka Valcheva
- Employees
- 73
- Market cap
- $1.3 B
- IPO
- 25/06/2021
GH Research PLC is a clinical-stage biopharmaceutical firm within the Healthcare sector that is dedicated to creating novel therapies for psychiatric and neurological conditions. Headquartered in Dublin, Ireland, the company was founded in 2018. The primary focus of its research activities involves developing…
Company description based on the data provider's company data, AI-assisted, created on 17/10/2026. Not investment advice.
GH Research stock: price history
1D
-5.3%
1W
-11.9%
1M
-30.3%
6M
+13.0%
YTD
+49.2%
1Y
+46.2%
2Y
+175.8%
5Y
+4.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~6% weaker price swings than usual
GH Research stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 24/09/2026.
Business model & megatrends
Business model with weaknesses or early megatrend headwind.
GH Research PLC is a clinical-stage biopharmaceutical company developing novel therapies for psychiatric and neurological disorders. The company's focus centers on researching 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT), particularly for treating treatment-resistant depression. GH Research is developing various drug delivery formats including inhalable, injectable, and intranasal products. While the lead candidate GH001 has advanced through clinical testing, candidates GH002 and GH003 remain in preclinical development. The company currently generates no revenue from product sales.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about GH Research
Analyst assessment of GH Research
PRICE TARGET LOW
US$39.00
CONSENSUS
US$48.83
MEDIAN
US$42.00
PRICE TARGET HIGH
US$65.00
0
STRONG BUY
9
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 07/08/2026
GH Research stock metrics
P/E
-18.95
P/B
3.51
EV/EBITDA
-15.46
RETURN ON EQUITY
-4.2%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
74.2%
FLOAT SHARES
50,879,451
AVG. DAILY VOLUME (30D)
272,127
Institutional holders
Comparable stocks
Frequently asked questions about GH Research stock
What does GH Research do?
GH Research PLC is a company in the Healthcare sector, Biotechnology industry, headquartered in Ireland.
The CEO is Velichka Valcheva, the company employs around 73 people.
The IPO was on 25/06/2021; the stock trades on NASDAQ under the ticker GHRS.
What do analysts say about GH Research stock?
9 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$48.83, ranging from US$39.00 to US$65.00, with a median of US$42.00.
This is an external assessment, not a statement by Market Jury.
When does GH Research report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -6% stronger than usual.
Does GH Research pay a dividend?
No, GH Research currently does not pay a dividend.
Which stocks are comparable to GH Research?
Comparable stocks include Jazz Pharmaceuticals, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get GH Research stock analyzed?
Clicking "Analyze stock" lets five strategies assess GH Research against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.